111 related articles for article (PubMed ID: 15831708)
1. Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse.
Wiesner SM; Jones JM; Hasz DE; Largaespada DA
Blood; 2005 Aug; 106(3):1054-62. PubMed ID: 15831708
[TBL] [Abstract][Full Text] [Related]
2. Vav promoter-tTA conditional transgene expression system for hematopoietic cells drives high level expression in developing B and T cells.
Kim WI; Wiesner SM; Largaespada DA
Exp Hematol; 2007 Aug; 35(8):1231-9. PubMed ID: 17560009
[TBL] [Abstract][Full Text] [Related]
3. Development of a lethal mast cell disease in mice reconstituted with bone marrow cells expressing the v-erbB oncogene.
von Rüden T; Kandels S; Radaszkiewicz T; Ullrich A; Wagner EF
Blood; 1992 Jun; 79(12):3145-58. PubMed ID: 1350740
[TBL] [Abstract][Full Text] [Related]
4. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
Zheng Y; Nong L; Liang L; Wang W; Li T
Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
[TBL] [Abstract][Full Text] [Related]
6. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.
Gerbaulet A; Wickenhauser C; Scholten J; Peschke K; Drube S; Horny HP; Kamradt T; Naumann R; Müller W; Krieg T; Waskow C; Hartmann K; Roers A
Blood; 2011 Feb; 117(6):2012-21. PubMed ID: 21148330
[TBL] [Abstract][Full Text] [Related]
7. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
Kim WI; Matise I; Diers MD; Largaespada DA
Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia.
Demehri S; Corbin A; Loriaux M; Druker BJ; Deininger MW
Exp Hematol; 2006 Mar; 34(3):284-8. PubMed ID: 16543062
[TBL] [Abstract][Full Text] [Related]
9. Xenobiotic response in humanized double transgenic mice expressing tetracycline-controlled transactivator and human CYP1B1.
Hwang DY; Chae KR; Shin DH; Hwang JH; Lim CH; Kim YJ; Kim BJ; Goo JS; Shin YY; Jang IS; Cho JS; Kim YK
Arch Biochem Biophys; 2001 Nov; 395(1):32-40. PubMed ID: 11673863
[TBL] [Abstract][Full Text] [Related]
10. Combining fibroblast isolation with lentiviral gene transfer to validate transgene expression in mice following pronucleus injection.
Rössler OG; Lesch A; Thiel G
Transgenic Res; 2016 Dec; 25(6):839-846. PubMed ID: 27506594
[TBL] [Abstract][Full Text] [Related]
11. Use of the tetracycline system for inducible protein synthesis in the kidney.
Gallagher AR; Schönig K; Brown N; Bujard H; Witzgall R
J Am Soc Nephrol; 2003 Aug; 14(8):2042-51. PubMed ID: 12874458
[TBL] [Abstract][Full Text] [Related]
12. Timing the doxycycline yields different patterns of genomic recombination in brain neurons with a new inducible Cre transgene.
Lindeberg J; Mattsson R; Ebendal T
J Neurosci Res; 2002 Apr; 68(2):248-53. PubMed ID: 11948670
[TBL] [Abstract][Full Text] [Related]
13. In vivo expression of a conditional TGF-beta1 transgene: no evidence for TGF-beta1 transgene expression in SM22alpha-tTA transgenic mice.
Lee S; Agah R; Xiao M; Frutkin AD; Kremen M; Shi H; Dichek DA
J Mol Cell Cardiol; 2006 Jan; 40(1):148-56. PubMed ID: 16288910
[TBL] [Abstract][Full Text] [Related]
14. Use of a new-generation reverse tetracycline transactivator system for quantitative control of conditional gene expression in the murine lung.
Duerr J; Gruner M; Schubert SC; Haberkorn U; Bujard H; Mall MA
Am J Respir Cell Mol Biol; 2011 Feb; 44(2):244-54. PubMed ID: 20395635
[TBL] [Abstract][Full Text] [Related]
15. Mast cell leukemia.
Georgin-Lavialle S; Lhermitte L; Dubreuil P; Chandesris MO; Hermine O; Damaj G
Blood; 2013 Feb; 121(8):1285-95. PubMed ID: 23243287
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
17. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
[TBL] [Abstract][Full Text] [Related]
18. The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells.
Ozer O; Zhao YD; Ostler KR; Akin C; Anastasi J; Vardiman JW; Godley LA
Leuk Lymphoma; 2008 Aug; 49(8):1567-77. PubMed ID: 18766971
[TBL] [Abstract][Full Text] [Related]
19. Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tTA and rTA linked to the keratin 5 promoter.
Diamond I; Owolabi T; Marco M; Lam C; Glick A
J Invest Dermatol; 2000 Nov; 115(5):788-94. PubMed ID: 11069615
[TBL] [Abstract][Full Text] [Related]
20. Conditional and inducible transgene expression in mice through the combinatorial use of Cre-mediated recombination and tetracycline induction.
Belteki G; Haigh J; Kabacs N; Haigh K; Sison K; Costantini F; Whitsett J; Quaggin SE; Nagy A
Nucleic Acids Res; 2005 Mar; 33(5):e51. PubMed ID: 15784609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
